325 related articles for article (PubMed ID: 30360663)
1. A review of ixekizumab in the treatment of psoriatic arthritis.
O'Rielly DD; Rahman P
Expert Rev Clin Immunol; 2018 Dec; 14(12):993-1002. PubMed ID: 30360663
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
van der Heijde D; Gladman DD; Kishimoto M; Okada M; Rathmann SS; Moriarty SR; Shuler CL; Carlier H; Benichou O; Mease PJ
J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
[TBL] [Abstract][Full Text] [Related]
3. The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2.
Deodhar A; Gladman D; Bolce R; Sandoval D; Park SY; Leage SL; Nash P; Poddubnyy D
Ther Adv Musculoskelet Dis; 2023; 15():1759720X231189005. PubMed ID: 37645684
[TBL] [Abstract][Full Text] [Related]
4. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
Smolen JS; Mease P; Tahir H; Schulze-Koops H; de la Torre I; Li L; Hojnik M; Sapin C; Okada M; Caporali R; Gratacós J; Goupille P; Liu Leage S; Pillai S; Nash P
Ann Rheum Dis; 2020 Oct; 79(10):1310-1319. PubMed ID: 32660977
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results.
Coates LC; Mease P; Kronbergs A; Helt C; Sandoval D; Park SY; Combe B; Nash P; Deodhar A
Clin Rheumatol; 2022 Oct; 41(10):3035-3047. PubMed ID: 35674861
[TBL] [Abstract][Full Text] [Related]
6. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
[TBL] [Abstract][Full Text] [Related]
7. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.
Toussirot E
Expert Opin Biol Ther; 2018 Jan; 18(1):101-107. PubMed ID: 29187009
[TBL] [Abstract][Full Text] [Related]
8. Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors.
Kirkham B; Sesin C; Gellett AM; Sprabery AT; Lin CY; Turkiewicz A
Rheumatology (Oxford); 2021 Sep; 60(9):4367-4372. PubMed ID: 33479721
[TBL] [Abstract][Full Text] [Related]
9. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS;
Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
[TBL] [Abstract][Full Text] [Related]
10. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Vu TT; Gooderham M; Papp K
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
[TBL] [Abstract][Full Text] [Related]
11. Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies.
Combe B; Tsai TF; Huffstutter JE; Sprabery AT; Lin CY; Park SY; Kronbergs A; Hufford MM; Nash P
Arthritis Res Ther; 2021 Jan; 23(1):41. PubMed ID: 33499913
[TBL] [Abstract][Full Text] [Related]
12. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis.
Combe B; Rahman P; Kameda H; Cañete JD; Gallo G; Agada N; Xu W; Genovese MC
Arthritis Res Ther; 2020 Jan; 22(1):14. PubMed ID: 31964419
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
Dougados M; Wei JC; Landewé R; Sieper J; Baraliakos X; Van den Bosch F; Maksymowych WP; Ermann J; Walsh JA; Tomita T; Deodhar A; van der Heijde D; Li X; Zhao F; Bertram CC; Gallo G; Carlier H; Gensler LS;
Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
[TBL] [Abstract][Full Text] [Related]
14. Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports.
Nagayasu A; Nawata M; Saito K; Tanaka Y
Mod Rheumatol Case Rep; 2020 Jul; 4(2):176-180. PubMed ID: 33086996
[TBL] [Abstract][Full Text] [Related]
15. Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study.
Joven B; Manteca CF; Rubio E; Raya E; Pérez A; Hernández R; Manrique S; Núñez M; Díaz-Cerezo S; Moyano S; Lacetera A; García-Vicuña R
Adv Ther; 2023 Dec; 40(12):5415-5431. PubMed ID: 37804475
[TBL] [Abstract][Full Text] [Related]
16. Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity.
Armstrong AW; Jaleel T; Merola JF; Gottlieb AB; Khattri S; Helt CC; Malatestinic WN; Ross SE; Ngantcha ME; de Vlam K
Dermatol Ther (Heidelb); 2024 Jun; 14(6):1615-1631. PubMed ID: 38814433
[TBL] [Abstract][Full Text] [Related]
17. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
Chandran V; van der Heijde D; Fleischmann RM; Lespessailles E; Helliwell PS; Kameda H; Burgos-Vargas R; Erickson JS; Rathmann SS; Sprabery AT; Birt JA; Shuler CL; Gallo G
Rheumatology (Oxford); 2020 Oct; 59(10):2774-2784. PubMed ID: 32031665
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study.
Smolen JS; Sebba A; Ruderman EM; Schulze-Koops H; Sapin C; Gellett AM; Sprabery AT; Li L; de la Torre I; Gallo G; Liu-Leage S; Pillai S; Reis P; Nash P
Rheumatol Ther; 2020 Dec; 7(4):1021-1035. PubMed ID: 33200394
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
[TBL] [Abstract][Full Text] [Related]
20. Ixekizumab in the treatment of psoriatic arthritis.
Lespessailles E; Toumi H
Immunotherapy; 2021 Jan; 13(1):19-33. PubMed ID: 33167745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
